Corticosteroids and central XXXX .

@entity1 @entity228 @entity699 @entity134 @entity989
PURPOSE: The purpose of this study is to investigate the relationship between corticosteroid use and central @entity989 (CSC). DESIGN: A prospective, case-controlled study. @entity1 AND CONTROLS: A consecutive series of @entity1 with acute manifestations of CSC and a control group matched for age, race, and gender were recruited between January 2000 and July 2000. METHODS: A detailed clinical history was taken, and fundus examination with slit-lamp biomicroscopy was performed on all @entity1 . Fluorescein angiography was obtained on the study @entity1 . RESULTS: A total of 50 @entity1 was recruited. Twenty-six @entity1 (52%) had a history of exogenous @entity134 use, including oral, intravenous, intranasal, and intraarticular administration. Two additional @entity1 had a history of endogenous @entity699 ( @entity699 ). In a matched control group, eight @entity1 (18%) had a history of @entity134 use. The difference in corticosteroid exposure between study @entity1 and controls was statistically significant (P < 0.0001). MAIN OUTCOME MEASURES: History of corticosteroid use or @entity699 . CONCLUSIONS: This study is consistent with previous reports associating @entity134 use with CSC. It identifies corticosteroids as a significant risk factor for the development of acute, exudative macular manifestation and implicates @entity699 as a factor in the pathogenesis of this disorder. Several forms of @entity228 administration were observed to be a risk factor for CSC. Accordingly, susceptible @entity1 in need of corticosteroids should be advised of the risk of developing acute manifestations of CSC.
